Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer
- Conditions
- Stage IV Non-small Cell Lung CancerRecurrent Non-small Cell Lung CancerStage IIIB Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT00062101
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
Erlotinib Plus Carboplatin and Paclitaxel in Ovarian Carcinoma
- Conditions
- Ovarian Mucinous CystadenocarcinomaOvarian Serous CystadenocarcinomaOvarian Undifferentiated AdenocarcinomaOvarian Endometrioid AdenocarcinomaBrenner TumorOvarian Clear Cell CystadenocarcinomaFallopian Tube CancerStage III Ovarian Epithelial CancerStage IV Ovarian Epithelial Cancer
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2015-12-01
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 56
- Registration Number
- NCT00059787
- Locations
- 🇺🇸
Montefiore Medical Center, Bronx, New York, United States
Erlotinib in Treating Patients With Locally Advanced or Metastatic Papillary Renal Cell Cancer
- Conditions
- Recurrent Renal Cell CancerStage III Renal Cell CancerStage IV Renal Cell Cancer
- Interventions
- Other: laboratory biomarker analysis
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-02-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 40
- Registration Number
- NCT00060307
- Locations
- 🇺🇸
Southwest Oncology Group, San Antonio, Texas, United States
A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
- Conditions
- Mucinous Adenocarcinoma of the RectumSignet Ring Adenocarcinoma of the ColonStage IIIC Rectal CancerMucinous Adenocarcinoma of the ColonStage IIIA Colon CancerStage IIIA Rectal CancerRecurrent Rectal CancerSignet Ring Adenocarcinoma of the RectumStage IIIB Rectal CancerStage IVB Colon Cancer
- Interventions
- Biological: bevacizumab
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2013-09-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT00060411
- Locations
- 🇺🇸
Johns Hopkins University, Baltimore, Maryland, United States
Erlotinib and Gemcitabine in Treating Patients With Metastatic Breast Cancer Previously Treated With An Anthracycline and/or a Taxane
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 61
- Registration Number
- NCT00059852
- Locations
- 🇺🇸
CCOP - Sioux Community Cancer Consortium, Sioux Falls, South Dakota, United States
🇺🇸CentraCare Health Plaza, Saint Cloud, Minnesota, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Erlotinib Plus Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Head and Neck Cancer
- Conditions
- Recurrent Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the Lip and Oral CavityStage IV Squamous Cell Carcinoma of the NasopharynxStage IV Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityRecurrent Salivary Gland CancerRecurrent Squamous Cell Carcinoma of the OropharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the Lip and Oral Cavity
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2013-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 45
- Registration Number
- NCT00055770
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Bevacizumab and Erlotinib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer
- Conditions
- Recurrent Squamous Cell Carcinoma of the OropharynxStage IV Squamous Cell Carcinoma of the HypopharynxStage IV Squamous Cell Carcinoma of the LarynxStage IV Squamous Cell Carcinoma of the Paranasal Sinus and Nasal CavityStage IV Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the HypopharynxRecurrent Squamous Cell Carcinoma of the LarynxRecurrent Squamous Cell Carcinoma of the NasopharynxRecurrent Squamous Cell Carcinoma of the Lip and Oral CavityRecurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity
- Interventions
- First Posted Date
- 2003-03-07
- Last Posted Date
- 2018-10-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 58
- Registration Number
- NCT00055913
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
Erlotinib in Treating Patients With Recurrent or Progressive Glioblastoma Multiforme
- Conditions
- Brain and Central Nervous System Tumors
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2014-01-10
- Lead Sponsor
- The Cleveland Clinic
- Target Recruit Count
- 73
- Registration Number
- NCT00054496
- Locations
- 🇺🇸
Cleveland Clinic Taussig Cancer Center, Cleveland, Ohio, United States
Erlotinib Plus Docetaxel in Treating Patients With Stage IV or Recurrent Breast Cancer
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- Paula Silverman, MD
- Target Recruit Count
- 39
- Registration Number
- NCT00054275
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer
- Conditions
- Stage IV Breast CancerRecurrent Breast Carcinoma
- Interventions
- First Posted Date
- 2003-02-06
- Last Posted Date
- 2017-07-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 38
- Registration Number
- NCT00054132
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸UCSF Medical Center-Mount Zion, San Francisco, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.